GlassScriptPhysician profile
Siobhan Yoshida
NPI 1881883205
$5,909.24
in general payments reported to CMS, 2019-2025
42 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $602 · 2022: $1,349 · 2023: $1,211 · 2024: $1,424 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,947 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,946.73 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $873.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $798.98 | 2021-2025 | |
| Astellas Pharma US INC | $470.01 | 2022-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $458.55 | 2021-2025 | |
| Lilly USA, LLC | $388.79 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $324.99 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $318.52 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $318.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $303.89 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.70 | 2021-2024 | Jardiance |
| Amarin Pharma, INC. | $155.58 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $146.34 | 2022 | |
| Amgen INC. | $102.64 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $93.12 | 2025 | |
| Corcept Therapeutics | $89.22 | 2022-2025 | Korlym |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siobhan Yoshida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.